AR882 for Gout Patients Who Have Not Responded to Prior Uricase Therapy

This open-label Phase 2 study is currently enrolling adults with uncontrolled gout who previously tried a uricase-based treatment

Duration

~ 6 months

Visits

6 – 8 clinic visits

Compensation

Yes, Provided

Location

Bellevue, WA

About This Trial

This open-label Phase 2 study is currently enrolling adults with uncontrolled gout who previously tried a uricase-based treatment (a medication that breaks down uric acid) but did not achieve adequate results.

Participants will receive AR882 together with an XOI (xanthine oxidase inhibitor), another uric acid-lowering medication, to evaluate the combination’s safety and effectiveness.

Because the study is open-label, all participants will know they are receiving the active treatment — there is no placebo group.

Condition: Uncontrolled Gout (prior uricase failure)

Learn more: View on ClinicalTrials.gov

Check Your Eligibility Screening

Answer a few questions to see if you may qualify for our gout clinical trial.

Eligibility screening is not available at the moment.

This is completely confidential, your answers are processed locally and are not stored or transmitted. Only your contact information is saved if you choose to submit it.

Other Trials

We have several clinical trials and you may be eligible for more than one. Lets find out.

AR882 for Gout Patients Who Have Not Responded to Prior Uricase Therapy

This open-label Phase 2 study is currently enrolling adults with uncontrolled gout who previously tried a uricase-based treatment

About This Trial

Check Your Eligibility Screening

Other Trials

Evaluating Sarilumab for Adults with Early Polymyalgia Rheumatica (PMR)

Testing Natrunix Combined with Methotrexate for Rheumatoid Arthritis

Using a Molecular Test to Guide Treatment Choice for Rheumatoid Arthritis

Continued Secukinumab Treatment for Prior Novartis Study Participants

V Secukinumab Safety Study for Giant Cell Arteritis or Polymyalgia Rheumatica

Testing a New Combination Treatment for Gout

Testing a New Treatment (LY3871801) for Moderate-to-Severe Rheumatoid Arthritis

Blood Sample Study for Rheumatoid Arthritis Patients Starting a New Medication

Testing LY2439821 for Moderate-to-Severe Plaque Psoriasis

Testing Nipocalimab for Moderate-to-Severe Sjögren’s Disease

Testing Afimetoran for Active Lupus (SLE)

Phase 3 Study of AR882 for Gout